IL-6 level as a marker for disease monitoring in patients with severe COVID-19

2020-04-03


The researcher community is currently working hard to fully understand the process of COVID-19 infection and its related immune response. Some recent articles highlight the importance of IL-6 measurement in this context.


When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines like IL-61. The increased expression of IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients2.

So the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-193.


In this respect, please remember the Demeditec Interleukin-6 human ELISA coded DE4640. For further product information, please click here.



Literature:

1 Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R,Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6)and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2):anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Mar 14;34(2)

2 Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, DengY, Wei S. Analysis of clinical features of 29 patients with 2019 novelcoronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005

3 Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, ZhengyuLi, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia, LilingZhang, Gang Wu, Jianhua Yi. The potential role of IL-6 in monitoring severecase of coronavirus disease 2019. medRxiv preprint doi:https://doi.org/10.1101/2020.03.01.20029769


Meilenstein - Demeditec-Logo 2017